

Myriad Genetics

JP Morgan Healthcare Conference 2021



Paul J. Diaz
President and CEO

January 11, 2021

Forward looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial guidance is provided under the investor section of Myriad's corporate website.

OUR MISSION AND OPPORTUNITY

“ *Our purpose-driven mission **to transform and improve lives** is more relevant than ever.*

We have a strong, compelling market opportunity as a leader in genetic testing and precision medicine.

But the market had been changing faster than we were.

We must transform to win, put patients and customers first, reset our base, simplify our business, and drive new commercial capabilities.

The new Myriad Genetics will create new growth opportunities for us all. ”

Paul J. Diaz
President and CEO





• A Powerful Thesis for Transformation

- Large, growing market opportunity - \$10B+
- Economics of molecular diagnostics support sustainable, profitable growth
- Respected portfolio, scientific know-how and reach
- Opportunities to elevate our products to full potential and advance new innovations
- Need to reset our competitive and financial position by reducing complexity and cost
- Winning culture and strong leadership team will be the foundation for delivering on our mission, market leadership, long-term growth and profitability

Four-point strategic roadmap

1 Put patients and customers first

2 Build new tech-enabled commercial capabilities

- Convey our unique value proposition
- Play offense with price positioning and reimbursement
- Ramp up consumer and digital marketing
- Enable frontline and virtual sales with best-in-class training and support


3 Elevate core products to full potential

- Increase awareness and access
- Bolster differentiation with messaging and innovation
- Reinforce clinical utility
- Maximize cross-sell and synergies across the portfolio

4 Create new avenues of growth

- Explore opportunities to invest in new products, innovations and technologies
- Direct-to-consumer marketing models
- Partnerships with payers, health systems, and other providers
- Dataset monetization

Transformation phases and objectives




A cohesive enterprise-wide commercial strategy framework

*Our business has to **consistently reinvent itself** and **adapt to evolving product lifecycles** to stay competitive and deliver **long-term profitable growth***



Deliver a crisp value proposition, aligned with customer needs



Reduce friction with customers through tech innovation



Optimize pricing and bring cost down to maximize operating income



Build a more effective and cost-efficient sales model



Develop capabilities to move towards direct-to-consumer



Build pipeline of new products to refuel growth

Three Focused Business Units

| | Women's Health | Oncology | Mental Health |
|---------------------|--|--|---|
| Mission | Serving women assessing risk of cancer and offering pre-natal tests for women | Genetic testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs. | Helping physicians understand how genetic alterations impact patient response to antidepressant and other drugs. |
| Market |  \$4B U.S Market Growing 10% |  \$4B U.S Market Growing 8% |  \$5B U.S Market Growing 15% |
| Products |     |      |  |
| Potential Catalysts | <ul style="list-style-type: none"> Improving prenatal economics Digital marketing and customer experience | <ul style="list-style-type: none"> Somatic strategy – tumor testing Prolaris reimbursement International CDx opportunity | <ul style="list-style-type: none"> Primary care expansion Pricing/reimbursement strategy Telehealth partnerships |

Women's Health Key Opportunities

Improving Prenatal Outlook

- **Prequel**® Amplify™ for prenatal testing
- Revenue cycle management, easier patient payment models
- Evidence Street recommendation for **Foresight**®
- ACOG recommendations for average risk prenatal testing



Foresight
MYRIAD
Prequel™
Prenatal Screen

Increasing Access, Reducing Disparities

- Expanding carrier screening to broaden access to testing
- Reducing healthcare disparities across racial, economic and social lines
- **riskScore**® global ancestry launch



riskScore™
BREAST CANCER

Customer Experience, Digital Marketing

- Accelerating the patient journey – interest to testing
- **myRisk**® portal
- Patient cost estimator
- AI counseling tools



Oncology Key Opportunities

myChoice CDx Kit Expanding Global Access

- Exclusive **myChoice® CDx** kit partnership with Illumina for select international markets




Polaris Reimbursement Prostate Cancer Testing

- Coverage for non-favorable intermediate and high-risk patients by Medicare




Companion Diagnostics International Expansion

- **myChoice® CDx** launch in Japan and Europe
- Pancreatic and prostate cancer approvals in Japan for **BRACAnalysis® CDx**





International Growth with Companion Diagnostics



- European lab tech-transfer deals in France/Germany for **myChoice® CDx**
- Illumina **myChoice® CDx** kit collaboration

- Japan now largest market outside U.S. with \$7.5M in revenue in Sep. (up 200% YoY)
- Pancreatic and prostate approvals double CDx target population in Japan
- Japanese approval of **myChoice® CDx**



MYRIAD
myChoice® CDx

Mental Health Key Opportunities

Pricing and Reimbursement



- Re-evaluating pricing and reimbursement strategy
- Value demonstration projects with payers

Telehealth Partnerships



- Expanding telehealth partnerships
- First signed in Sept. '20




Primary Care Expansion



- Sales rep additions
- Direct-to-consumer marketing initiatives
- Increased focus on inside sales

GeneSight Primary Care Launch

... **TARGET CLINICIANS** | Top antidepressant prescribers - high United Healthcare/Medicare potential



Seamless Tech-Enabled Customer Experience

Education

Telehealth

Access

Portals



Technology Enabled Customer Initiatives




Education

MyGeneHistory - Risk assessment at home or in clinic, EMR integration, AI-driven guides, Personalized workflow




Telehealth

Tele-Psychiatry partnerships to facilitate test orders



Access

Transparent, personalized out of pocket cost estimates



Portals

Patient and provider portals for results delivery and order management.

30% reduction in time per order

EMR scale-out to 275+ new interfaces

MYRIAD
myRisk®
Hereditary Cancer

riskScore™
BREAST CANCER

genesight®

Foresight

MYRIAD
Prequel™
Prenatal Screen

Driving digital engagement and conversion


Myriad.com

Enhancing the experience



Hereditary Cancer Quiz

Driving follow through



GROWTH OPPORTUNITY

1.7% who take quiz and meet national (NCCN) criteria convert to complete myRisk tests.

myRisk® Patient journey - Current State




“Katie”

34 years old, worried
but never had cancer



“I have a lot of
cancer in my
family, I wonder
if I’m at risk too”



Searches to see
how to get tested



“Visits
Myriad.com to
take Hereditary
Cancer Quiz”



Qualifies for
test

Now What?

Virtual appointment with a
physician

Learn more through educational
resources

No action and drops off



**Current Conversion
rate: 1.7%**

myRisk® Patient journey – Future State



“Katie”

34 years old, worried
but never had cancer



Sees targeted ads
on social media



Visits
Myriad.com to
check risk per
family history



Qualifies for test
& receives
real-time cost
estimate



Personal
follow-up call
from Myriad
within 24 hours

Scenario 1 **Has a physician**

1.0 Katie gets test kit
delivered. Takes to physician

1.1 Katie wants information.
Talks to Myriad rep. Katie or
rep contacts physician.

Scenario 2 **2 - No Physician**

2.0 Myriad rep helps Katie
find a physician

2.2 Katie gets a call from
Genetic Counselor,
Physician, or Nurse. Kit
order facilitated.

● Announced Divestitures – Increasing Core Focus


 myriad® | RBM

 myriad® | AUTOIMMUNE

 myriad® | DERMATOLOGY

- Simplifies the business, improves execution
- Slightly accretive without capital deployment
- Substantial cash proceeds for reinvestment
- Significant inbound interest; likely to close in 1H CY21

Key Drivers Impacting Operating Income in CY21



Unlocking the power of
genetics to improve and
transform lives



Q & A